Clinical Immunology Communications最新文献_第3页

Serum immunoglobulin levels and risk of antibiotic prescription in middle-aged and older individuals: A population-based cohort study 中老年个体血清免疫球蛋白水平和抗生素处方风险:一项基于人群的队列研究

Clinical Immunology Communications Pub Date : 2023-07-22 DOI: 10.1016/j.clicom.2023.07.003

Anna Vanoverschelde , Samer R. Khan , Virgil A.S.H. Dalm , Layal Chaker , Guy Brusselle , Bruno H. Stricker , Lies Lahousse

{"title":"Serum immunoglobulin levels and risk of antibiotic prescription in middle-aged and older individuals: A population-based cohort study","authors":"Anna Vanoverschelde , Samer R. Khan , Virgil A.S.H. Dalm , Layal Chaker , Guy Brusselle , Bruno H. Stricker , Lies Lahousse","doi":"10.1016/j.clicom.2023.07.003","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.07.003","url":null,"abstract":"<div><h3>Objectives</h3><p>Elderly become more susceptible to lower respiratory tract infections, resulting in antibiotic prescriptions. Immunoglobulins (Ig) play an important role in host defense and protection against infections. Therefore, we aimed to investigate whether lower Ig levels are a risk factor for antibiotic use in the general elderly population.</p></div><div><h3>Methods</h3><p>After exclusion of current antibiotic users, Cox proportional-hazards regression models were performed to investigate the effect of stable serum IgM, IgG and IgA levels on time to first antibiotic prescription within the Rotterdam Study. Regression models were adjusted for age, sex, body mass index, smoking status and diabetes. We introduced quadratic terms and additionally categorized Igs to explore and quantify potential non-linearity of the association. The restricted cubic splines technique was used to plot the natural log of the hazard across Ig level.</p></div><div><h3>Results</h3><p>In total, 8,639 participants were included (mean age 64 years, 57% female, medium follow-up 3.2 years). No significant association between IgM and time to antibiotic prescription was observed. IgG and IgA levels (in g/L) showed a U-shaped relationship with time to antibiotic prescription (linear IgG HR 0.959, 95% CI 0.930–0.989; quadratic IgG² HR 1.002, 95% CI 1.000–1.003; linear IgA HR 0.949, 95% CI 0.910–0.990; quadratic IgA² HR 1.009, 95% CI 1.004–1.013).</p></div><div><h3>Conclusion</h3><p>Both low and high IgG and IgA levels were associated with a higher incidence of antibiotic prescriptions in stable middle-aged and older individuals. Increased awareness for the potential increased infection risk when persons have low or high Ig levels, even within the reference ranges, is needed.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49752593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunopathogenesis of cutaneous T-cell lymphoma in skin of color patients part 2: Sézary syndrome 有色皮肤患者皮肤t细胞淋巴瘤的免疫发病机制。第二部分:ssamzary综合征

Clinical Immunology Communications Pub Date : 2023-07-22 DOI: 10.1016/j.clicom.2023.07.002

Nina C. Nwade , Sachi I. Desse , Akanksha Nagarkar , Nia E.R. James , Ryan Svoboda , Ginette A. Okoye , Jillian M. Richmond , Angel S. Byrd

引用次数: 0

Immunopathogenesis of cutaneous T-cell lymphoma in skin of color patients part 1: Mycosis fungoides 有色皮肤患者皮肤t细胞淋巴瘤的免疫发病机制第一部分:蕈样真菌病

Clinical Immunology Communications Pub Date : 2023-07-20 DOI: 10.1016/j.clicom.2023.07.004

Sachi I. Desse , Nina C. Nwade , Akanksha Nagarkar , Nia E.R. James , Ryan Svoboda , Ginette A. Okoye , Angel S. Byrd , Jillian M. Richmond

引用次数: 0

Cross-protective immunity induced by omicron variant of SARS-CoV-2 SARS-CoV-2组粒变异诱导的交叉保护性免疫

Clinical Immunology Communications Pub Date : 2023-07-20 DOI: 10.1016/j.clicom.2023.07.007

Selia Chowdhury , Md. Shahraj Chowdhury , Nurjahan Shipa Chowdhury , Samia Chowdhury , Shajeda Chowdhury

引用次数: 0

IL-23 Inhibitors to treat psoriatic arthritis: A systematic review & meta-analysis of randomized controlled trials IL-23抑制剂治疗银屑病关节炎:随机对照试验的系统回顾和荟萃分析

Clinical Immunology Communications Pub Date : 2023-07-20 DOI: 10.1016/j.clicom.2023.07.001

Ahmed Safi Vahidy , Faizan Niaz , Samiuddin Tariq , Irtebaat Fatima , Yusra Afzal , Abdulqadir J. Nashwan

{"title":"IL-23 Inhibitors to treat psoriatic arthritis: A systematic review & meta-analysis of randomized controlled trials","authors":"Ahmed Safi Vahidy , Faizan Niaz , Samiuddin Tariq , Irtebaat Fatima , Yusra Afzal , Abdulqadir J. Nashwan","doi":"10.1016/j.clicom.2023.07.001","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.07.001","url":null,"abstract":"<div><h3>Aim</h3><p>To review the available evidence on the efficacy and safety profiles of four Interleukin-23 inhibitors in patients with Psoriatic Arthritis.</p></div><div><h3>Methods</h3><p>Several databases were searched till July 2022. A total of 11 RCTs with at least one treatment arm were included. All articles were in English. The primary outcomes were ACR20, HAQ-DI, PASI90, and TEAEs experienced by the patients.</p></div><div><h3>Results</h3><p>Compared to other groups, Guselkumab had the strongest association with ACR20 response (RR: 2.14; 95% CI: 1.84-2.49, <em>p < 0.00001</em>), while a mean change in HAQ-DI (MD: -0.24; 95% CI: -0.41- -0.13, <em>p = 0.0001</em>) and PASI90 (RR: 9.81; 95% CI: 3.18-30.22; <em>p <0.01</em>) were most strongly associated with Ustekinumab. TEAEs were significantly present in the Guselkumab group (RR: 1.26; 95% CI: 1.00 - 1.59; <em>p = 0.05</em>).</p></div><div><h3>Conclusion</h3><p>Although our analysis suggests that IL-23 inhibitors are efficacious at treating psoriatic arthritis, further studies are required for long-term outcomes.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49753108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

B cell depletion in infants after intra uterine exposure to immunomodulating chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): A case series and review of the literature 子宫内暴露于利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松(R-CHOP)免疫调节化疗后的婴儿B细胞耗竭:病例系列和文献回顾

Clinical Immunology Communications Pub Date : 2023-06-22 DOI: 10.1016/j.clicom.2023.06.004

Jantien W. Wieringa , Mirjam J. Esser , Jan G.M.C. Damoiseaux , Gertjan A. Driessen , Joyce J.B.C. van Beers

引用次数: 1

Considerations on COVID-19 vaccination COVID-19疫苗接种的考虑

Clinical Immunology Communications Pub Date : 2023-06-10 DOI: 10.1016/j.clicom.2023.06.003

Antonio La Cava

引用次数: 0

Aptamer: A theranostic approach towards breast cancer 适配体:一种治疗乳腺癌的方法

Clinical Immunology Communications Pub Date : 2023-06-03 DOI: 10.1016/j.clicom.2023.06.002

Shubhi Rana, Deepti Kaushik, Aprajita Singh, Deeksha Gautam, Janhavi Rai, Jitendra Singh Rathore

{"title":"Aptamer: A theranostic approach towards breast cancer","authors":"Shubhi Rana, Deepti Kaushik, Aprajita Singh, Deeksha Gautam, Janhavi Rai, Jitendra Singh Rathore","doi":"10.1016/j.clicom.2023.06.002","DOIUrl":"https://doi.org/10.1016/j.clicom.2023.06.002","url":null,"abstract":"<div><p>Breast cancer has a heavy toll on the world's health, both in terms of morbidity and death. For women aged 35 to 54, it is the primary cause of mortality. In addition, over the preceding 2 decades, the mortality rate has not decreased noticeably. Early diagnosis and detection are still essential for enhancing patient outcomes despite substantial advancements in treatment. Also, possible to use monoclonal antibodies, but they come with a host of drawbacks, including unspecified binding, toxicity, expense, and debated clinical efficacy. Aptamers, which are small nucleic acid molecules that can bind to specific target molecules with high specificity, have instead emerged as potential theranostic treatments for breast cancer. Both for diagnosis and treatment, aptamers can be made to precisely target breast cancer cells or molecules linked to tumor progression. High binding affinity and specificity, low immunogenicity, and ease of modification are just a few of the characteristics that set aptamers apart from other delivery systems and make them desirable options for the delivery of drugs, imaging agents, or both, to breast cancer cells. In this study, we provide a comprehensive overview of the aptamer-based theranostic strategies for treating breast cancer, including aptamer selection, modifications, and imaging and drug delivery applications.</p><p>We also discussed the SELEX method for picking aptamers and why they are good breast cancer treatments. The toxicity and weak immunogenicity of some antigens do not affect aptamer selection, unlike antibodies. Compared to antibodies, they are more selective and have higher affinities. Therefore, in the future, these therapies may be used as both main therapies and adjuvants to traditional anti-HER2 therapies. We also discussed the difficulties and potential futures of theranostic approaches based on aptamers for treating breast cancer.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49767283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nailfold capillary dropout precedes the presentation of pneumatosis intestinalis and micro-perforation in juvenile dermatomyositis 在青少年皮肌炎中，甲襞毛细血管脱落先于肠肺病和微穿孔的出现

Clinical Immunology Communications Pub Date : 2023-06-03 DOI: 10.1016/j.clicom.2023.06.001

Andi Wang , Amer Khojah , Gabrielle Morgan , Lauren M. Pachman

引用次数: 4

Erratum regarding missing Informed Consent Statements and Conflict of Interest Statements in previously published articles 关于先前发表的文章中缺少知情同意声明和利益冲突声明的勘误表

Clinical Immunology Communications Pub Date : 2023-05-20 DOI: 10.1016/j.clicom.2023.05.001

引用次数: 0